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ABSTRACT 
The free plasma amino acid profiles of 8 nasopharyngeal 
cancer patients, 8 lung cancer patients, 12 breast cancer 
patients and 8 colorectal cancer patients were studied by 
reversed-phase High-Performance Liquid Chromatography. 
These cancer patients were all newly-diagnosed. The results 
were compared with those obtained from a control group of 
23 healthy and disease-free volunteers. The nasopharyngeal 
cancer patients showed a decrease in the concentrations of 
aromatic amino acids (tyrosine, tryptophan, phenylalanine), 
essential amino acids (valine, tryptophan, phenylalanine) 
and the main glucogenic amino acid glycine. The lung cancer 
patients had amino acid profiles similar to those of the 
control group. The breast cancer patients had elevated 
total amino acid concentrations, but such elevation was not 
due to the increase of any specific types of amino acid. 
The colorectal cancer patients showed the greatest changes 
in amino acid profile: there were decreases in total amino 
acid concentrations, in the concentrations of aromatic 
amino acids (tyrosine, tryptophan, phenylalanine), 
essential amino acids (threonine, valine, tryptophan, 
phenylalanine, lysine), and alanine, which is another main 
glucogenic amino acid. The branched-chain amino acids 
(leucine, isoleucine and valine) in the four types of 
cancer patient were maintained in similar levels as in the 
controls. This study shows that there were definite 
alterations in the free plasma amino acid profiles of 




1.1 METABOLIC DERANGEMENTS AND CACHEXIA IN CANCER 
Many metabolic processes are markedly altered in cancer 
patients. Common disturbances that have been observed in 
cancer include hypercalcaemia, uraemia, the hyperviscosity 
syndrome, and syndromes resulting from ectopi.c production 
of hormones, such as Cushing's Syndrome and Syndrome of 
Inappropriate Antidiuretic Hormone Secretion (SIADH) 
(Galton, 1987). Disorders in electrolytes and water 
metabolism, lactic acidosis, hypomagnesaemia, and 
hyperuricaemia are also commonly found in cancer patients 
(Uribarri and Carroll, 1991). 
Derangements in lipid, carbohydrate and protein metabolism 
are often observed (Lundholm et al., 1981; Bourgeois et 
al., 1992; Goldberg and Diamandis, 1993). Reduction in body 
fat and protein wasting resulting from these disturbances 
eventually lead to cancer cachexia. 
The word cachexia, which was derived from two Greek words 
"kakos" and "hexis" meaning "poor condition of the body", 
is now used to describe the host wasting that occurs in 
many disease states. Clinical features of cancer cachexia 
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include anorexia, weight loss, muscle weakness, anaemia and 
pyrexia. 
The pathogenesis of metabolic disturbances in malignancy, 
and subsequently, cancer cachexia, is probably multi-
factorial and several explanations have been put forward. 
In a study by Brennan (1977), it was found that the normal 
adaptive mechanisms seen in patients with simple starvation 
were impaired in cancer patients with uncontrolled cancer 
growth. In another study, Warnold et al. (1978) showed that 
cancer patients had a higher resting metabolic rate and 
daily energy expenditure than heal thy controls who took 
comparable physical activity. Similarly, Waterhouse (1974) 
found that energy expenditure, basal oxygen consumption, 
and CO2 production were all inappropriately high for the 
nutritional status of the cancer patients they 
inve s t igated. These result s suggest that the inability of 
cancer patients to alter their metabolic regulatory 
functions for adaptation to the undernourished state caused 
by a norexia or malabsorption, may be a factor causing 
cancer cachexia. 
A s tudy by Cos ta ( 1977), howe ver, f ound that t he loss o f 
adipose tissue and muscle frequently took place before a 
detectable fall in food intake; suggesting t ha t cancer 
cachexia was not simply a result of semi-starvation. 
2 
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Another factor that has been proposed as contributory to 
cancer cachexia is insulin resistance. Copeland et al. 
(1988) showed that patients 
malignancy demonstrated impaired 
with gastrointestinal 
post-operative glucose 
disposal and a reduced insulin response during steady-state 
hyperglycaemia when compared with the control subjects. 
They suggested that resistance to insulin, a major anabolic 
hormone, might play a role in causing impaired glucose 
disposal in cancer patients. In a study by Selberg et al. 
(1990), weight-losing cancer patients had a higher 
palmitate turnover, a decreased plasma insulin 
concentration but an increased cortisol level before and 
during glucose loading, when compared with subjects in the 
control group. They proposed that the enhanced body fat 
mobilization in cancer patients might be mediated by the 
altered plasma concentrations of insulin and cortisol. 
Results from other studies suggested that cancer cachexia 
might be mediated by various cytokines (formally called 
cachectin), which are endogenous peptides produced by 
activated macrophages within tumour tissues. In a study by 
McCall et al. (1992), patients with gastrointestinal cancer 
were significantly more insulin-resistant than controls. 
Their insulin resistance correlated with their serum levels 




1.2 PROTEIN METABOLISM IN MALIGNANCY 
Normally, man is in a state of nitrogen balance; with the 
rate of protein synthesis equal to that of degradation. The 
situation in cancer, however, is more complicated. Results 
of standard nitrogen studies in cancer patients are 
difficult to interpret because such protocols cannot 
distinguish between utilization of nitrogen intake by host 
tissues or tumour tissues. 
In a study to assess protein metabolism in patients at 
different stages of colorectal carcinoma (Carmichael et 
al., 1980), protein turnover was found to be increased with 
advancement of the disease. All the patients were in 
positive nitrogen balance, despite anthropometric data 
suggesting loss of host body protein. The authors proposed 
an explanation: that there was translocation of protein 
stores from muscle to tissues where there was rapid protein 
synthesis such as tumour tissues. 
Jeevanandam et al. (1984) also showed that the rate of 
protein turnover and protein synthesis were higher in 
cancer than in non-cancer patients or in normal healthy 
subjects in starvation. 
4 
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In order to examine the selective utilization of nutrients 
by host and tumour tissue, Cram-Smith et al. (1977) used 
tumour-bearing rats and labelled amino acids to study the 
protein synthetic rates in different body tissues. They 
found that tumour-bearing rats on an adequate diet had a 
decreased muscle protein synthesis but an increased hepat i c 
protein synthesis. They proposed that the increase in 
hepatic protein synthesis was due to a general increase in 
the turnover rate of hepatic enzymes. 
Wi th redistribution of body proteins in cancer, there 
should be some alterations in the plasma amino acid levels 
in cancer patients. 
1.3 REVIEW OF REPORTS ON AMINO ACID DISTURBANCES IN 
MALIGNANCY 
In a study by Ching et al. (1984), patients with early 
stage head-neck tumour were shown to have plasma amino acid 
profiles similar to those of the control subjects except 
for a deficiency in threonine and glycine. The authors 
attributed such observations to the effect of dysphagia on 
the nutritional intake of these patients. Hepatic cancer 
patients undergoing chemotherapy and/or radiation ther apy, 
however, were noted to have significantly decre ased l eve l s 
of the essential amino acids valine, l eucine, threonine, 
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and methionine, and the non-essential amino acids serine, 
glycine, and proline. 
In another study, Norton et al. (1985) showed that in 
cancer patients with lymphoma, osteosarcoma and sarcoma 
(with no, or minimal weight loss), levels of most plasma 
amino acids, except for proline, were similar to those of 
the controls. Esophageal cancer patients with weight loss, 
however, demonstrated a 35% decrease in totai amino acid 
levels and marked reduction in most circulating amino 
acids. The levels of the two essential branched-chain amino 
acids valine and leucine, however, remained normal. 
Al though these patients all suffered significant weight 
loss, the authors ruled out malnutrition as the only cause 
for the amino acid changes, because in malnutrition there 
should have been greater loss of essential than non-
essential amino acids. 
Naini et al. (1988) found that in patients with lung or 
esophageal cancer, the pre-operative concentrations of most 
plasma free amino acids, except tryptophan, were similar to 
those in patients with non-malignant diseases. The decrease 
in tryptophan was explained by the investigators to be due 
to its uptake by the tumour mass for 5-hydroxyindolacetic 
acid synthesis. After operation, the concentrations of 
glutamine, tryptophan, alanine, glycine, and a r gini ne fell 
sharply, whereas those of phenylalanine, lysi n e , v a line , 
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and leucine were slightly or not affected by surgery. The 
authors attributed the post-operative changes in the 
concentrations of these amino acids to the increased rate 
of gluconeogenesis after surgery. Alanine and glycine are 
the main substrates for gluconeogenesis. The same reason 
was used to explain why the concentrations of branched-
chain amino acids such as valine and leucine were 
maintained normal in malignancy. The main site of 
metabolism for branched-chain amino acids is the muscle, 
they are not taken up by the liver for glucose synthesis. 
The interpretation of the above findings on branched-chain 
amino acids, however, was not supported by the results of 
an earlier report which studied the disappearance of 
radioactive-labelled leucine from the plasma of patients 
with malignant cancer, and later, its appearance in expired 
air (Waterhouse and Mason, 1981). The authors reported that 
leucine metabolism, p~esumably an example of branched-chain 
amino acid metabolism, appeared to be accelerated in 
patients with cancer and weight loss. 
In a study on serum amino acid levels in cirrhotic patients 
with and without hepatocellular carcinoma, elevation of 
methionine, phenylalanine and tyrosine levels was observed 
in cirrhotic patients without hepatocellular carcinoma 
(HCC), but there was no such increase in cirrhot i c patient s 
with HCC (Watanabe et al.,1984). The authors suggested t hat 
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there might be a characteristic serum amino acid pattern in 
cirrhotic patients with HCC, resulted from the increased 
consumption of amino acids by the tumour. 




different primary cancer sites 
head/neck, breast), the plasma 





cysteine, alanine, arginine 
pattern that correlated with 
and 
the 
specific malignant diseases. The investigators therefore 
proposed that plasma free amino acid patterns could be used 
for diagnosis and, in case of a metastatic lesion, to 
indicate a possible origin of the primary site. 
In another study, Zhang and Pang (1992) showed that the 
amino acid pattern of breast cancer patients was similar to 
that of the healthy ~ontrols. However, in liver and colon 
cancer patients, while the levels of plasma branched-chain 
amino acids, leucine, isole ucine and valine, which ar~ 
metabolized predominantly by the muscle, did not decrease, 
that of many other amino acids increased. The authors 
suggested that the increase was caused by diminished 
hepatic enzyme activities for oxidati ve degradation of 
these amino acids, as well as possibly their decreased 
utilization fo r p r otein s ynt hesis i n t he liver. A different 
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pattern was observed in lung cancer patients. The 
concentrations of ten amino acids, most of them essential, 
were significantly lower than normal. 
In summary, there are still no consistent plasma or serum 
amino acid patterns reported in malignancy, except that 
patients with early stage, extra-intestinal malignancies 
appear to have less changes in their amino acid profiles. 
Studies of amino acid profiles in malignancy patients 
should be of value because if characteristic amino acid 
patterns are found, they may be used for diagnosis. If not, 
knowing the amino acid profiles of cancer patients may be 
useful for the assessment of their nutritional status and 
hence formulation of the most appropriate diet. 
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1.4 AMINO ACID ANALYSIS BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
The application of column chromatography to amino acid 
analysis was first described in 1951 by Moore and Stein. 
They separated amino acid mixtures on sulfonated cation-
exchange resin by a series of elution buffers with 
increasing pH. In 1958, together with Spackman (Spackman et 
al., 1958) they described the construction of an automatic 
recording analyzer for recording the colour intensity 
developed by reacting ninhydrin with the amino acid 
effluent from the ion-exchange column. This set-up formed 
the basis of the development of many analyzers dedicated 
for amino acid analysis. 
In the 1970s, the advent of high performance liquid 
chromatography (HPLC) provided a rapid and effective 
separation technique. Attempts to apply HPLC techniques to 
amino acid analysis have resulted in many workable 
protocols. There are mainly two types of technical 




1.4.1 Amino Acid Analysis by Ion-Exchange HPLC 
Analysis of free amino acids in physiological fluids had 
presented difficulties due to their low concentrations. 
with the introduction of resin with bead particles of 
uniform diameter of less than 10 ~m in HPLC techniques, 
analytical sensitivity was improved almost a hundred fold. 
Hughes et al. (1982) were among the first workers to 
demonstrate successful applications of the ion-exchange 
HPLC technique to analysis of amino acids in physiological 
fluids. They used a series of elution buffers of increasing 
ionic strength and pH to generate a step gradient elution 
profile. 
However, the step gradient elution systems used by very 
early workers required preparation of several buffers with 
precisely controlled pH and ionic strength; and transition 
from one buffer to another might lead to baseline shifts 
which subsequently interfered with quanti tation of the 
chromatographic peaks. 
The use of conventional peristal tic pumps for preparing 
gradient elution profiles (Klapper, 1982) requires only two 
buffer systems and eliminates artefact peaks caused by pH 
transition. with the use of microprocessor-controlled 
pumps, the mixing of solvents is now even more precise, 
resulting in stable baseline (M~ller, 199 3 ) . 
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At acidic pH, ionization of the carboxyl groups of amino 
acids is suppressed, and amino acids are retained on the 
sulfonated column via their amino groups which are ionized. 
since acidic amino acids have weaker interaction with the 
sulfonated group, they are eluted first, followed by the 
hydroxylated, the neutral and, finally, the basic amino 
acids. 
Free amino acids are not readily detectable after 
fractionation. Most amino acids only absorb at short 
wavelength «220 nm) but so do many other organic solvents 
such as methanol and acetonitrile (Grasselli, 1975), thus 
detection at this wavelength is not specific. The aromatic 
amino acids, phenylalanine, tyrosine and tryptophan, absorb 
light in the 250-280 nm region but the other amino acids do 
not. Derivatization is, therefore, necessary to render the 
amino acids detectable. With ion-exchange HPLC, post-column 
derivatization is usually used. Ninhydrin used to be the 
most commonly used post-column derivatization reagent, but 
is gradually being replaced by fluorogenic agents such as 
o r tho- pht ha l a lde hyde a nd f luorescami n e . These deriv a t izing 
agents will be discussed in more detail in Section 1.4.3. 
Ion-exchange amino acid analysis followed by post-column 
reaction using chromogenic or fluorogenic agents i s a 
reliable technique. However , the method is l abour-intensive 
and requires dedicated i nstrumenta t ion. The effluent 
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velocity and subsequently the analysis time are limited by 
the mechanical strength of the resin which cannot withstand 
excessive pressure (Ersser and Davey, 1991). The post-
column derivatizing reaction inevitably increases the 
volume of the eluate and may lead to less satisfactory 
resolution. Sensitivity of this method is generally limited 
by the ability to obtain high-purity elution buffers. When 
working at the picomolar levels, trace buffer contaminants 
can cause significant baseline shift (Pfeifer and Hill, 
1983) • 
1.4.2 Amino Acid Analysis by Reversed-Phase HPLC 
Currently, more than 70% of modern HPLC separations are 
carried out in the reversed-phase mode utilizing 
alkysilycated silica particles (Tanaka and Araki, 1989). 
wi th reversed-phase HPLC, separations are achieved on a 
stationary hydrophobic bonded surface using a more polar 
mobile phase for elution. He nc e , retention of a compound . 
increases with the increase in non-polarity of that 
compound. 
For ionic species such as acids and bases, their 
interactions with the non-polar stationary phase are 
insufficient to give e f fective r esolution . If they are to 
13 
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be made amenable to separation by rever sed-phase HPLC~ they 
have to be converted to their more hydrophobic form. One 
method is by total suppression of ionization: by c hoosing 
a pH lower than t he pKa o f the acids or a pH higher than 
the pKa of the bases. Since the working pH r ange for bonded 
phase silica packing is 2 to 8, this technique of ion 
suppression is only useful f o r weak acids and weak bases. 
However, amino acids are zwitterions with the pKa of the 
acid function less than 5 and the pKa of the amino function 
greater than 8. Hence, there is no pH at which ionization 
of both function groups can be suppressed simultaneously 
(Pfeifer and Hill, 1983 ) . 
In order to' make amino acids amenable to separation on 
reversed-phase HPLC, t he technique of pre-column 
derivatization was introduced. A derivatizing reagent is 
covalently bonded to either the carboxylic or the amino 
f uncti onal group to destroy the zwitterion form. The 
derivatives formed should also be detectable fluorophores 
or chromophores so that specific and sensitive detection of 
the separated amino acid components is possible. It is 
important that the derivatizing reaction produces a unique 
product for each amino acid. 
In general, reversed-phase separation of pre-derivatized 
amino acids enjoys several advanta ges over t he ion-exchange 
post-column derivatization technique : sensitiv ity of s ub-
1 4 
Introduction 
picomolar level can be achieved, analysis time is shorter, 
peak width can be minimized, baseline fluctuations are 
less, the equipment is not dedicated and, hence, can be 
used for the analysis of other substances (Turnell and 
Cooper, 1982; Pfeifer and Hill, 1983; Sarwar and Botting, 
1993). 
1.4.3 Derivatizing Agents 
with amino acids, pre or post-column derivatization agents 
have been used. Conventionally, post-column derivatization 
is used after ion-exchange separation, and pre-column 
deri vatization is used before reversed-phase HPLC. When 
used post-column, after ion-exchange separation, it does 
not matter if the derivatizing reagent forms non-unique 
products with the amino acids in the sample, because these 
components have already been separated. When used pre-
column, before reversed-phase separation, it is important 
that the derivatizing reaction produces a unique product 
for each amino acid. If the reaction yields more than one 
product for an amino acid, these products may have 
different polarity and will appear as different peaks after 
separation, thus quantitation of the amino acid will be 
difficult. Likewise, if several amino acids yield the s ame 
product, identification and quanti tation o f these amino 
acids will be impossible (Pfeifer and Hill, 1983 ) . 
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Commonly used derivatizing agents for amino acid analysis 
include ninhydrin, o-phthalaldehyde (OPA), dansyl chloride 
(Dns-Cl), fluroenyl-methyl chloroformate (FMOC), phenyl-
isothiocyanate (PITC), and fluorescamine. 
Ninhydrin used to be the most commonly used post-column 
derivatization reagent but is gradually being replaced by 
fluorogenic agents. The amino group of the amino acid 
reacts with two molecules of hydrindantin (the reduced form 
of ninhydrin) to form the Rhuman's purple chromogen 
(MacFadyen and Fowler, 1950), which is measured 
photometrically in the visible region (570 nm for primary 
amino acids and 440 nm for secondary amino acids). 
Quantitative detection down to 200 pmol is possible. 
However, the ninhydrin reaction requires an elevated 
reaction temperature and long reaction time. It is usually 
carried out at 95°C for 30 minutes (Deyl et al., 1986). 
Ortho-Phthalaldehyde (OPA) was first used as a post-column 
derivatizing agent for amino acids by Roth (1971). In the 
presence of a reducing agent, OPA reacts with primary " 
amines to form thiol-substituted iso-indoles which are 
highly fluorescent (Simons and Johnsons, 1978). The 
reaction takes place at room temperature in less than 5 
minutes. OPA itself is not fluorescent and hence will not 
produce interfering peaks. Sensitivity down to femtomolar 
level has been achieved. However, OPA does not react with 
16 
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secondary amines such as proline and hydroxyproline, unless 
they are first reduced with hypochlorite. OPA derivatives 
are also unstable and hence detection cannot be delayed 
after the reaction has been started (Roth, 1971; Sarwar and 
Botting, 1993). Nowadays, OPA is more commonly used in pre-
column derivatization of amino acids in reversed-phased 
HPLC (Hogan et al., 1982; Blundell and Brydon, 1987; Georgi 
et al., 1993). 
5-Dime~hylaminoapthalene-1-sulfonyl chloride, commonly 
called dansyl chloride (Dns-CI), reacts with both primary 
and secondary amino acids to give derivatives which are 
both highly fluorescent and UV absorbing. The reaction can 
be carried out at room temperature and the derivatives, 
once formed, are stable for at least 96 hours. However, the 
derivatization process takes as long as 50 minutes 
(Wiedmeier et al., 1982). Detection at the low picomolar 
level has been achieved (Oray et al., 1983). 
The reaction of fluroenylmethyl chloroformate (FMOC) with 
amino acids can be completed in 30 seconds and the 
fluorescent derivatives formed are stable for over 10 days. 
The detection limit is in the low femtomolar range. 
However, the reagent itself is fluorescent so any excess 
reagent has to be removed before HPLC analysis (Einarsson 
et al., 1983). 
17 
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Phenylisothiocyanate (PITC) reacts with both primary and 
secondary amino acids to form derivatives that absorb UV at 
254 nm. The reaction takes only 5 minutes at room 
temperature and the derivatives formed are stable enough to 
eliminate any need for in-line derivatization (Henrikson 
and Meredith, 1984; Hariharan, 1993). 
Fluorescamine reacts with primary amines almost 
ins t antaneously at room t emperature . The products are 
highly fluorescent, and primary amines in the picomolar 
range can be detected (Udenfriend et al., 1972). 
The main advantages of fluorogenic or chromogenic reagents 
over the traditional ninhydrin are that they require a 
shorter reaction time and lower reaction temperature. They 
are also significantly cheaper. However, some of the 
fluorogenic agents cannot react with all the amino acids 
(Benson and Hare, 1975). 
18 
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1. 5 CHOICE OF CANCER PATIENTS AND METHODOLOGY FOR THIS 
STUDY 
1.5.1 Choice of Cancer Patients 
This work was intended to further study the changes in 
amino acid profiles in five types of cancer: naso-
pharyngeal, lung, breast, 
colorectal cancers. 
liver (non-cirrhotic) and 
Only newly-diagnosed patients that were free of cardiac, 
hepatic, renal, metabolic and endocrine diseases and had 
not received any chemotherapy or radiotherapy were to be 
recruited. It was hoped that this would minimize variables, 
other than malignancy, that might cause changes in amino 
acid concentrations. 
The cancer types chosen for this study are all solid 
tumours of high incidence in Hong Kong. According to the 
figures from the Hong Kong Department of Health in 1990, . 
lung cancer was the leading cause of cancer mortality i n 
men (33%), followed by liver (16%) and colorectal cancer 
(9%); nasopharyngeal cancer (6%) was the sixth commonest. 
In women, the leading cause of cancer death was also lung 
cancer (26%), followed by colorectal (12%), breast (8%) and 




1.5.2 Methodology Chosen and Its Principle 
Reversed-phase HPLC was chosen as the technique for the 
separation of plasma amino acids in this study instead of 
ion-exchange HPLC because the former has the advantages of 
higher sensitivity, smaller eluant volume, more stable 
baseline, and greater versatility (Section 1.4.2). 
o-Phthalaldehyde (OPA) was chosen as the pre-column 
derivatizing agent because its reaction with amino acids 
has high fluorescent yield, short reaction time (0.5 min) 
at room temperature and high sensitivity (fmol). OPA itself 
is not fluorescent and hence will not produce interfering 
peaks (Sarwar and Botting, 1993). 
In the presence of a thiol-containing reducing agent, such 
as 2-mercaptoethanol (ME), OPA reacts with primary amino 
acids to give intensely fluorescent products with optimal 
excitation wavelength at 340 nm, and emission wavelength at 
450 nm. However, OPA does not react with secondary amines -
such as proline and hydroxyproline, unless they are first 
reduced with hypochlorite (Roth, 1971). 
The fluorescent product is a 1-alkythio-2-alkyl-substituted 
isoindole formed between the amino group of the primary 
amino acid and an OPA-ME adduct (Fig. 1.1). The addition 
'sequence of the reaction is important; the best results are 
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obtained by mixing OPA and thiol before adding the amine 
(Simons and Johnson, 1978). However, the isoindoles formed 
are unstable due to a suI fur-oxygen rearrangement which 
produces a non-fluorescent 2, 3-dihydro-1H-isoindole-1-one 3 
(Simons and Johnson, 1978). Special arrangements, 
therefore, have to be made in the sampling process to 
standardize and to minimize the time interval between 
injection and the completion of the reaction of the OPA-ME 
adduct and sample. An automated method is usually used for 









R = alkyl 
+ H2NR 
R'SH 





R' = alkyl or aryl 
Introduction 
SR' 
cC~ N-R ~ ~ 
Isoindole derivative 
Fig. 1.1 The reaction between o-phthalaldehyde and 
primary amine in the presence of a thiol reagent to form 1-
alkythio-2-alkyl-substituted isoindole. H~R = primary 
amine, R'SH = thiol reagent. 
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2. OBJECTIVES 
I. To establish a reversed-phase HPLC method for plasma 
amino acid analysis. 
11. To establish the plasma amino acid profiles in naso-
pharyngeal, lung, breast, liver (non-cirrhotic) and 
colorectal cancer patients in Hong Kong. 
Ill. To assess the diagnostic values and organ specificity 
of plasma amino acid profiles. 
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3. MATERIALS AND METHODS 
3.1 STUDY SUBJECTS 
3.1.1 Patients 
Newly-diagnosed cancer patients free of cardiac, hepatic, 
renal, metabolic and endocrine diseases were recruited into 
this study before treatments such as surgery, chemotherapy 
or radiotherapy. Patient selection, based on clinical 
features and histopathological data, was carried out by 
clinical oncologists in the Department of Clinical 
Oncology, Princes of Wales Hospital. They also collected 
the clinical data. The patients were recruited over nine 
months from January to September 1993. 
There were 8 nasopharyngeal cancer patients (6 males and 2 
females, aged 31-74 years, median age 42); 8 lung cancer 
patients (all males, aged 53-74 years, median age 62); 12 
breast cancer patients (all females, aged 24-93 years, 
median age 53) and 8 colorectal cancer patients (5 males 
and 3 females, aged 32-80 years, median age 61). All the 
newly-diagnosed liver cancer patients within this period 
also had liver cirrhosis. In view of the metabolic 
complications caused by liver cirrhosis, results of plasma 
free amino acid profiles would be difficult to interpret 
and therefore these patients were excluded from the study. 
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3.1.2 Control Subjects 
Twenty-three healthy and disease-free volunteers (10 males, 
aged 24-60 years, median age 35; and 13 females, aged 20-54 
years, median age 32) were recruited to serve as the 
control group. 
3.2 CLINICAL FEATURES 
Anthropometric measurements (weight, height, triceps 
skinfold, and arm-muscle circumference) of the patients 
were recorded at the time of diagnosis. Weight changes 
during the previous month before diagnosis were also 
recorded. All these data were collected by clinical 
oncologists. 
3.3 BLOOD COLLECTION 
About 20 mL morning fasting blood was obtained by " 
venepuncture from each patient and healthy volunteer. For 
the cancer patients, blood collection was taken -immediately 
after diagnosis before treatments such as surgery, 
chemotherapy or radiotherapy. Ten mL o f blood was 
transferred into a heparin bott l e and the remaining 10 mL 
into a plain tube. Afte r c e ntrifugation, the plasma and 
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serum were aliquoted into I-mL portions and stored at -70°C 
before analysis to prevent hydrolysis of labile amino acids 
such as glutamine (Ukida et al.,1981). The plasma samples 
were stored for not more than three months prior to 
analysis for free amino acids. 
3.4 GENERAL BIOCHEMICAL TESTS 
Liver function tests and renal function tests were 
performed for each patient and control. Their nutritional 
status were also assessed by the determination of serum 
iron, total iron binding capacity (TIBC) and ferritin. 
3.5 PLASMA AMINO ACID ANALYSIS BY HPLC 
3.5.1 Apparatus 
An automated HPLC s ystem was used (Wate rs Assoc., Milford, ' 
MA, U. S .A. ). It consisted of two Model 6000A solvent ' 
delivery systems, a Model 710B sample processor (WISP), a 
Model 420-AC fluorescence detector, a system interface \ 
module and a Maxima 820 chromatography chemstation. 
The analytical c olumn was a rev ersed-ph ase C'8 PIca. TAG 
column (3.9 mm I.D. x 15 cm length, 4 ~m particle size) 
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supplied by Waters Associates. The column was installed in 
a temperature 'controller and equipped with a guard column 
immediately in front of it (both from Waters). The packing 
material in both the analytical and the guard columns was 
dimethyloctadecylsilyl bonded amorphous silica. 
Water purification was performed with a Milli-Q Reagent 
Water System (Millipore, Bedford, MA, U.S.A). 
3.5.2 Reagents 
Acetonitrile and methanol (both of chromatography grade) 
were obtained from E. Merck (Darmstadt, Germany). Anhydrous 
o-phthaladehyde, DL-amino acids and sodium propionate were 
obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.); 
2-mercaptoethanol was from E. Merck. Other chemicals such 
as sodium dihydrogen phosphate, sodium hydroxide, dimethyl -
sulphoxide and boric acid were of analytical grade from BDH 
Ltd. (Poole, England) or E. Merck. 
Fluorocarbon membrane and nitrocellulose membrane for 
filtering reagents were 
Corporation, '(MA, U.S.A . ). 
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High purity helium (99.995% pure) for mobile phase 
degassing was obtained from Hong Kong Oxygen and Acetylene 
Co. Ltd. (Clear Water Bay, Hong Kong). 
3.5.3 Reagent Preparation 
3.5.3.1 Mobile phase 
Elution was carried out by gradient and flow programming of 
two delivery solvents which made up the mobile phase. 
Delivery solvent A consisted of acetonitrile, sodium 
propionate/phosphate buffer and water (8:15:77 by volume). 
The sodium propionate/phosphate buffer contained 0.25 M 
sodium propionate and 0.35 M sodium dihydrogen phosphate, 
pH 6.5. 
Delivery solvent B consisted of acetonitrile, methanol, 
dimethylsulphoxide (DMSO) and water (30:25:3:42 by volume). ' 
The organic solvents had been filtered through a 0.22 ~m 
fluorocarbon membrane and the inorganic reagents through a \ 
0.45 ~m nitrocellulose membrane. They were then mixed to 
prepare the delivery solvents. 
The delivery solvents were degassed with helium before use. 
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3.5.3.2 Derivatizing reagent 
A stock solution of o-phthalaldehyde (OPA) was first 
prepared by dissolving 50 mg of anhydrous OPA in 1 mL of 
methanol in an amber bottle. This solutiori was stable for 
three weeks when kept at 4°C in the dark. 
To prepare 1.56 mL of the OPA-ME solution for 
derivatization, 60 ~L of OPA stock solution was first added 
to 1476 ~L of 0.4 M sodium borate/boric acid buffer (pH 
9.5); and then, in a fume hood, 24 ~L of 2-mercaptoethanol 
(ME) was added. This OPA-ME solution was also kept in the 
dark and was stable for only one day. 
3.5.4 Standard Preparation 
3.5.4.1 Internal standard solution 
Two internal standards, homoserine and norvaline, were -
incorporated into each standard and test solution. 
A stock solution containing 600 ~M homoserine and 600 ~M 
norvaline in 0.1 M HCl was first prepared, aliquoted and 
stored at -70°C. 
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A working internal standard solution was freshly prepared 
just before analysis by a ten-fold dilution of the stock 
solution with methanol. 
3.5.4.2 Composite standard solution 
Two levels of composite standard solution, each consisting 
of 28 amino acids as listed in Table 3.1, were used for 
peak identification and for calibration of the peak 
responses relative to the internal standards. 
Stock solutions of individual amino acids, all with a 
concentration of 40 ~mol/mL, were first prepared in 0.1 M 
hydrochloric acid, aliquoted, and kept at -70°C. 
Two levels of stock composite standard solution were then 
prepared by mixing the appropriate volume of individual 
amino acid stock solutions with 0.1 M HCI, aliquoted, and 
kept at -70°C. 
Just before analysis, the two levels of stock composite 
standard solution were each diluted ten-fold with methanol 
to prepare two levels of working composite standard 
solution with the final concentration of individual amino 
acids as shown in Table 3. 1. The concentra t ion of each 
amino acid in level 2 was five times of that i n level 1 . 
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Table 3. 1 Concentrations of Amino Acids in Working 



























































































Materials and methods 
3.5.4.3 Composite standard-internal standard mixture 
Just before HPLC analysis, 100 f..lL of working composite 
standard (Section 3.5.4.2) was transferred to an Eppendorf 
vial and to it was added 40 f..lL of working internal standard 
solution (Section 3.5.4.1) to prepare the composite 
standard-internal standard mixture. 
3.5.5 Sample Preparation 
3.5.5.1 Protein removal 
Proteins were precipitated from plasma samples by adding 
one volume of plasma to nine volumes of methanol in a 
1.5 mL Eppendorf vial. The mixture was vortexed and then 
centrifuged at 2500 x g for 5 min. 
3.5.5.2 Addition of internal standard 
A 100-f..lL aliquot of the supernatant was then transferred to 
40 f..lL of working internal standard solution (Section 
3.5.4.1) in a 1.5 mL Eppendorf vial. 
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3.5.6 Preparation of Samples for the WISP Sample Processor 
About 100 pL of each composite standard-internal standard 
mixture (Section 3.5.4.3) or test-internal standard mixture 
(Section 3.5.5) was placed in a small-volume sample insert 
(Water Associates) which was then secured in a 4-mL 
reaction vial by a compression spring. The reaction vial 
was screw-capped with an open-top cap sealed by a silicone 
septum. 
The light-sensitive OPA-ME solution (Section 3.5.3.2) was 
prepared in an amber-coloured 4-mL reaction vials. One vial 
of OPA-ME solution was needed for each vial of standard or 
test solution. 
The vials were placed onto the sample carriage of the WISP 
sample processor according to a sample queue as described 
in Section 3.5.7. 
3.5.7 Sample Queue for the WISP Sample Processor 
Due to variation in equilibrium time, the result of the 
first HPLC run on a practical day is generally not 
representative of the following runs. A methanol sample , 
therefore, was injected into the HPLC s y s t em for a blank 
run of 80 minutes to equilibrate the system. 
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The second and third runs were the two levels of composite 
standard solution, and other samples followed. 
Immediately before each vial of standard or test solution 
was placed a vial of OPA-ME solution for automated pre-
column derivatization. 
A typical sample queue programmed onto the WISP sample 
processor was shown in Table 3.2. 
Each patient sample was analyzed twice on two d i fferent 
days. The mean of the two results obtained was taken as the 
final result. The samples were not segregated according to 
the cancer type but analyzed in random order. 
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* The 710B WISP sample processor 6an hold up to 40 vials. 
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3.5.8 Automated Derivatization Procedure 
The WISP sample processor was programmed to charge the 
sample loop with 8 ~L of the OPA-ME derivatizing reagent at 
zero run time. One minute later, the sampler injected 8 ~L 
of a sample solution into the loop. Mixing, and reaction 
between the sample and the derivatizing reagent, thus, took 
place in the tubing and guard column, on-line, prior to 
separation in the HPLC column. 
3.5.9 Chromatographic Conditions 
The two delivery solvents, A and B, were mixed to obtain 
the mobile phase with a flow and gradient profile as shown 
in Table 3.3. The analytical column was maintained at 30°C. 
The Model 420-AC fluorescence detector was set at an 
excitation wavelength of 338 nm, and an emission wavelength 
of 420 nm. The run time for each standard or test sample 
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Delivery solvent A: Acetonitrile, sodium propionate(0.25M)/ 
phosphate buffer(0.35M), pH 6.5, water (8:15:77 v/v/v). 
Delivery solvent B: Acetonitrile, methanol, dimethylsulph-
oxide and water (30:25:3:42 v/v/v/v). 
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3.6 STATISTICAL STUDIES 
The mean amino acid concentrations of each subject were 
calculated from the results of the two different HPLC runs. 
The mean result in each cancer patient group was computed. 
Since the sample sizes of the cancer groups in this study 
were small, the Central Limit Theorem in statistics could 
not be applied directly because it stated that 'If 
sufficiently large random samples are taken from any 
infinitely large population with a finite variance, sample 
mean has a approximately normal distribution' (Shott, 
1990). In order to determine whether the data distributions 
of the cancer groups were normal or not, the data were 
plotted into histograms. If their distributions were close 
to normality, Student's t Test would be used to compare the 
mean concentration of each amino acid in each cancer group 
with that of the normal heal thy controls. If there was 
large deviation from normality, the Mann Whi tney U Test 
(McCall, 1992) would be used to compare the distributions 
of the cancer groups with that of the control group. Mann 
Whitney U Test is the non-parametric counterpart of the 
Student's t Test, it makes no assumptfon to the \ 
distribution of the underlying population. 
Amino acids were also grouped into branched-chain amino 
acids (valine + leucine + isoleucine), aromatic amino acids 
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(phenylalanine + tyrosine + tryptophan), essential amino 
acids (valine + leucine + isoleucine + phenylalanine + 
tryptophan + threonine + lysine), and non-essential amino 
acids (glutamic acid + glutamine + glycine + alanine + 
serine + asparagine + tyrosine) for comparison. Methionine 
was not included into the essential amino acid group and 
aspartic acid not into the non-essential amino acid group 
because of their low concentrations in plasma. In addition, 
the total free amino acid concentration in each patient was 




4.1 ANALYTICAL PERFORMANCES 
4.1.1 Chromatograms 
The resolution for the 28 amino acids was satisfactory 
except that there was partial overlap in the peaks of 
citrulline and arginine, and of valine and methionine. 
A typical chromatogram of the composite standard level 2 
(Section 3.5.4.2) and of a normal plasma sample are shown 
in Figures 4.1 and 4.2 respectively. Typical chromatograms 
of a nasopharyngeal cancer patient, a lung cancer patient, 
a breast cancer patient and a colorectal cancer patient are 
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x :10 1 Minutes 
Fig. 4.1 : Chromatographic separation of composite Amino 
Acid Standard Level 2. Concentrations as listed under Table 
3.1. Column: Reversed-phase CI8 PICO.TAG column kept at 30°C (3.9 mm I.D. x 15 cm length, 4 Mm particle size, waters 
ASsoc.). Mobile phase A: Acetonitrile, sodium p~opionate 
(0. 25M) /phosphate buffer (0. 35M), pH 6.5, water (8: 15: 77 
v/v/v). Mobile phase B: Acetonitrile, methanol, dimethyl-
sulphoxide and water (30:25:3:42 v/v/v/v). Flow programme 
as described under Table 3.3. Detector: 420-AC Fluorescence 
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conditions as described in Fig. 
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Fig. 4. 3 A Typical Chromatogram of a Nasopharyngeal 
Cancer Patient. Chromatographic conditions as described in 














·Fig. 4.4 : A Typical Chromatogram of a Lung Cancer Patient. 
Chromatographic conditions as described in Fig. 4.1. 
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A plasma sample was analyzed ten times on the same day to 
obtain the within-day precision and four times on four 
separate days to obtain the between-day precision. 
The within-day C. V. (coefficient of variation) for the 
amino acids ranged from 2.4 to 8.0% (Table 4 .. 1), and the 
between-day C.V. from 2.9 to 13.4% (Table 4.2). 
4.1.3 Linearity 
A series of standard solutions with concentrations as 
listed under Table 4.3 were analyzed to obtain the 
linearity. 
The concentrations of amino acids were plotted against 
their peak responses and the coefficients of correlation 
(r) were calculated. The coefficients of correlation (rt 
ranged from 0.988 to 0.998 within the concentration ranges 
investigated (Table 4.3). 
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ND Not detected in the plasma sample used 
'_I Data not available 
ADA Amino adipic acid 
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56.9 ± 2.1 
58.4 ± 4.3 
91.8 ± 8.5 
155.6 ± 8.0 
76.0 ± 6.2 
184.6 ± 11.8 
ND . 
ND 
S.D. Standard deviation 
C.V. Coefficient of variation 
ND Not detected in the plasma sample used 
'_I Data not available 


























Table 4.3 : Linearity Studies. The concentration ranges 
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4.1.4 Analytical Recovery 
The analytical recovery of the system was studied by 
spiking 100 ~L of a pooled plasma sample with 100 ~L of 
composite standard level 2 (Section 3.5.4.2). Concentration 
of amino acid added varied from 200 to 1000 ~mol/L. 
Percentage of recovery for each amino acid was calculated 
by the following formula: 
Amount of amino acid recovered 
% recovery = xlOO% 
Amount of amino acid added (known) 
Where 
Amino acid recovered = 
Amino acid in spiked sample - Amino acid in pooled plasma 
(measured) (measured) 
Percentages of recovery obtained were between 90-119% 






























































































4.2 DATA DISTRIBUTION STUDIES 
Most of the histograms plotted with the data of the cancer 
patients were so skewed that normal distribution of amino 
acid levels in the cancer population could not be inferred 
just from these data. Hence, the Mann Whitney U Test, which 
made no assumption to the distribution of the underlying 
population, was used for comparison of the patients' 
results. Some of the histograms were shown in Fig. 4.7. 
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AT LEAST 195.500 . 5 10 15 20 25 30 35 40 
BUT NOT OVER: F'REQ 1- +-----+-----+------+-----+-----+------+-----+-----+ 
268.500 1 12.5 IXXXXXXXXXXXXXXXX 
341.~00 2 25.0 IXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
414.500 0 00.0 I 
487.500 2 25.0 IXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 
560.500 3 37.5 IXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX +-----+-----+------+-----+-----+------+-----+-----+ 
TOTAL 8 100.0 5 10 15 20 25 30 35 40 
a) Histogram of alanine level in nasopharyngeal cancer 
patients. 
AT LEAST 























10 20 30 41) 50 
b) Histogram of serine level in lung cancer patients. 
AT LEAST 
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c) Hist~gram of glycine level in breast cancer patients. 
AT LEAST 
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10 20 30 40 50 60 70 
d) Histogram of valine level in colorectal cancer 
patients. 
Fig. 4.7 Histograms of Some Amino Acids. 
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4.3 PATIENTS' ANTHROPOMETRIC DATA AND BLOOD BIOCHEMISTRY 
Tables 4.5 to 4.8 summarize the patients' . anthropometric 
data and some biochemical test results. Anthropometric data 
shown include weight, percentage weight loss over the 
previous month before diagnosis, triceps skinfold which 
evaluates one's fat store and arm-muscle circumference 
which evaluates one's lean body mass. Biochemical test 
results shown are those that can reflect partially the 
patients' nutritional status (Iron, TIBe, total protein and 
albumin) . 
Patients in the nasopharyngeal cancer group had no or 
minimal «5%) weight loss. One patient, however, had 
reduced serum iron and plasma albumin concentrations. 
In the lung cancer group, two patients had significant 
weight loss during the previous month before diagnosis (9% 
and 19.8% respectively). These two patients also had low 
serum iron and plasma albumin concentrations. Anothex 
patient was also low in iron and albumin concentrations, " 
but his weight was maintained. 
In the breast cancer group, one patient had significant 
weight loss (12.5%) and marginally low serum iron and 
plasma albumin conce ntrations. Anothe r t wo pat i ents , 
although weight-stable, also had low iro n concentrations . 
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Patients in the colorectal cancer group had no or just 
minimal «5%) weight loss. All the patients, however, had 
low or marginally low albumin levels. Three patients had 
marginally low serum iron levels. 
Results of liver function tests and renal function tests of 
these patients (not shown) were all found to be normal. 
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Table 4.5 : Anthropometric Data and Blood Biochemistry of 
Nasopharyngeal Cancer Patients 
Anthropometric data Blood Biochemistry 
------------------------------------------
Case Sex Age wt Wt! TSF AMC Iron TIBC TP ALB 
(yr) (kg) ( % ) (mm) (cm) (J1mol/L) (g/L) 
-----------------------------------------------------------
1 M 31 64 0 11 28 27 60 82 
2 M 32 66 0 4 30 23 51 76 
3 M 39 68 3.3 10 31 19 63 82 
4 M 41 62 1.6 6 25 18 57 80 
5 M 42 54 0 7 26 22 53 81 
6 M 65 60 1.6 7 26 21 54 84 
7 F 57 41 0 1 22 10 52 83 
8 F 74 44 0 1 24 3 41 76 
wt! = % Weight loss over the month before diagnosis. 
TSF = Triceps Skinfold, AMC = Arm-Muscle Circumference. 
Iron and TIBC were measured with serum sample. 









Reference Ranges: Serum Iron: 6-30 J1mol/Li Serum TIBC: 40-
73 J1mol/Li Plasma Total Protein: 66-81 g/Li Plasma Albumin: 
36-48 g/L. 
Table 4.6 : Anthropometric Data and Blood Biochemistry of 
Lung Cancer Patients 
-----------------------------------------------------------
Anthropometric data Blood Biochemistry 
------------------------------------------
Case Sex Age wt Wt! TSF AMC Iron TIBC TP ALB 
(yr) (kg) ( % ) (mm) (cm) (J1mol/L) (g/L) 
-----------------------------------------------------------
1 M 53 48 0 2 22 2 48 85 30 
2 M 59 76 0 4 28 17 50 85 39 .-
3 M 61 45 0 4 24 24 10 80 43 
4 M 63 49 0 2 23 10 48 81 38 
5 M 63 51 9.0 5 23 5 34 67 23 
6 M 69 46 19.8 3 22 3 3·5 76 23 
7 M 71 52 0 5 22 7 5 2 79 32 \ 
8 M 74 42 2.3 2 18 28 72 74 38 
Legend: Same as that for Table 4.5 
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Table 4.7 : Anthropometric Data and Blood Biochemistry of 
Breast Cancer Patients 
---------------------------------------------------------
Anthropometric data Blood Biochemistry 
------------------------------------------
Case Sex Age Wt Wtl TSF AMC Iron TIBC TP ALB 
(yr) (kg) (% ) (mm) (cm) (Jjmol/L) (g/L) 
-----------------------------------------------------------
1 F 24 46 96 87 43 
2 F 42 16 75 73 40 
3 F 29 81 46 
4 F 31 60 0 33 21 16 58 75 37 
5 F 32 42 0 34 14 82 34 
6 F 34 51 0 29 20 18 5"3 80 42 
7 F 57 64 12.5 40 21 7 54 81 34 
8 F 59 52 0 28 18 10 57 60 46 
9 F 66 46 0 6 62 66 39 
10 F 78 56 0 6 43 69 38 
11 F 86 45 0 23 16 73 35 
12 F 93 9 49 68 34 
-----------------------------------------------------------
Legend: Same as that for Table 4.5 
'-' : Data not available 
Table 4.8 : Anthropometric Data and 
Colorectal Cancer Patients 
Blood Biochemistry of 
-----------------------------------------------------------
Anthropometric data Blood Biochemistry 
------------------------------------------
Case Sex Age wt Wt! TSF AMC Iron TIBC TP ALB 
(yr) (kg) ( % ) (mm) (cm) (Jjmol/L) (g/L) 
-----------------------------------------------------------
1 M 49 46 3.8 2 21 7 43 66 37 
2 M 61 44 0 7 24 8 56 72 32 
3 M 61 52 0 3 25 23 70 78 39 ' 
4 M 69 56 0 4 26 
5 M 80 46 0 4 21 
6 F 32 48 0 6 23 
7 F 56 64 0 5 25 
8 F 67 60 1.5 10 25 
Legend: Same as that for Table 4.5 
'-' : Data not available 
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4.4 FREE PLASMA AMINO ACID CONCENTRATIONS IN NORMAL 
CONTROLS 
The free plasma amino acid concentrations of male and 
female normal controls are listed in Table 4.9. There were 
ten amino acids which were significantly different in 
concentration between the male and female controls. They 
included glutamic acid, histidine, citrullin~, tyrosine, 
valine, methionine, tryptophan, isoleucine, leucine and 
lysine. Except for glutamic acid which was higher, all were 
of a lower concentration in the female controls. After 
grouping amino acids into specific groups as described in 
Section 3.6, the concentrations were also significantly 
lower in the female than in the male controls. The total 
amino acid concentrations were different at P < 0.02, the 
branched-chain amino acid concentrations at P < 0.01, the 
aromatic amino acid concentrations at P < 0.05 and the 
essential amino acid concentrations at P < 0.01. 
4.5 FREE PLASMA AMINO ACID CONCENTRATIONS IN CANCER 
PATIENTS 
The free plasma amino acid concentrations in cancer 
patients are grouped in Tables 4.10 to 4.13. Si nce there 
were ten amino acids which the male and female controls 
were significantly different in concentration (Section 
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4.4), the free plasma amino acid concentrations in lung 
cancer patients, who were all males, were compared with the 
concentrations of the male controls (Table 4.11). For the 
same reason, the results of the breast cancer patients were 
compared with the female controls. (Table 4.12). For the 
colorectal and nasopharyngeal patients, since the sample 
sizes were small, the results were not further divided by 
sex for comparison. Their group results were compared with 
that of the whole control group (Table 4.10 and 4.13). 
In the nasopharyngeal cancer group, the concentrations of 
eight amino acids were significantly lower than those in 
the control group (Table 4. 10). They were asparagine, 
serine, glycine, tyrosine, a-amino-butyric acid, valine, 
tryptophan, and phenylalanine. After grouping amino acids 
into specific groups (Section 3.6), the aromatic amino acid 
and essential amino acid concentrations were also 
significantly lower in the cancer patients (at P < 0.01 and 
P < 0.05 respectively). 
As can be seen in Table 4.6, there were two lung cancer 
patients with significant weight loss (9.0% and 19.8% 
respectively). Preliminary statistical studies showed that 
if their re suI ts were inc I uded into the results of the 
whole group of lung cancer patients, the concentrations of 
eight amino acids (glutamic acid, histidine, threonine, 
alanine, tyrosine, a-aminobutyric acid, tryptophan and 
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lysine), the total amino acid concentration and the 
essential amino acid concentration in the lung cancer group 
were significantly different from those of the normal 
controls. However, if the results of these two patients 
were excluded, only four amino acid concentrations (that of 
histidine, threonine, a-aminobutyric acid and lysine) were 
significantly different (Table 4. 11), and there was no 
significant difference in the total amino acid and 
essential amino acid concentrations between the lung cancer 
patients and the control subjects. Since the control 
subjects were all stable in weight, it was decided not to 
include the results of lung cancer patients with weight 
loss for comparison with the control group. For the same 
reason, the results of one breast cancer patient who 
suffered significant weight loss (12.5%) were also 
excluded. 
After excl uding the results of the two patients with 
significant weight loss, histidine, threonine, a-amino-
butyric acid and lysi ne in lung cancer pati ents wer.e 
significantly lower in concentration than in the control" 
subjects. After grouping into specific amino acid groups, 
however, there were no significant differences between th~ 
cancer and control groups. 
In the breast cancer patient group, the concentrations of 
seven amino acids (glutamic acid , serine, histidine, 
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citrulline, taurine, phenylalanine and ornithine) were 
significantly different in concentration from those in the 
female controls (Table 4.12). Except for glutamic acid and 
serine, their concentrations in the breast cancer group 
were all higher than in the female control group. Their 
total amino acid concentrations were also significantly 
different (P < 0.05). After grouping into specific amino 
acid groups, the branched-chain, aromatic and essential 
amino acid concentrations were similar between the cancer 
and control groups. 
In the colorectal cancer group, the concentrations of ten 
amino acids were significantly different from those in the 
normal controls (Table 4.13). They were asparagine, 
threonine, 3-methyl-histidine, alanine, taurine, tyrosine, 
valine, tryptophan, phenylalanine and lysine. Except for 
taurine, they were all lower in the colorectal cancer 
group. After grouping, the total amino acid concentrations 
were significantly different at P < 0.05, aromatic amino 
acid concentrations at P < 0.01 and essential amino aci~ 
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± 19. 6a 
± 122..-0c 
0.05 c 
a-c Concentrations significantly different from that in 
male controls (Mann-Whitney U Test). 
a : at P < 0.05 
b : at P < 0.02 
c : at P < 0.01 
Amino acids included in total amino acid, branched-chain, 
aromatic, essential, and non-essential amino acids were 
defined in Section 3.6. 
EAA/NEAA : Ratio of essential to non-essential amino acids . 
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Table 4. 10 Plasma Amino Acid Concentrations in Naso-
pharyngeal Cancer Patients (6 males, 2 females). (Compared 
with normal controls) 
Normal control Nasopharynx cancer 

























Mean ± S.D. 
40.3 ± 18.8 
50.1 ± 10.1 
129.2 ± 16.6 
79.9 ± 17.3 
777.1 ± 119.0 
249.2 ± 43.7 
150.7 ± 29.5 
30.2 ± 10.0 
66.4 ± 13.0 
15.2 ± 8.3 
409.7 ± 89.3 
49.6 ± 10.9 
65.4 ± 12.7 
25.8 ± 8.5 
358.2 ± 81.5 
11.8 ± 4.7 
59.1 ± 10.1 
63.0 ± 11.4 
71.2 ± 15.3 
131.3 ± 25.1 
57.1 ± 15.8 
177.0 ± 32.3 
Conc.(J..lmol/L) 
Mean ± S.D. 
47.0 ± 16.6 
39.3 ± 11.lb 
104.5 ± 14.3d 
72.9 ± 14.5 
844.4 ± 67.8 
194.6 ± 38. 1 c 
110.3 ± 41.3 
30.1 ± 10.2 
55.6 ± 12.6 
20.5 ± 12.3 
414.6 ± 125.9 
52.8 ± 9.7 
49.1 ± 9.3 c 
19.8 ± 6. la 
297.2 ± 35.5a 
ND 
51.2 ± 10.4a 
54.4 ± 8.7b 
69.2 ± 7.4 
118.3 ± 19.0 
55.7 ± 13.9 
161.0 ± 30.0 
------------------- ------------------------------------
Total amino acid 3227.3 ± 624.0 2861.5 ± 410.7 
Branched-chain 552.1 ± 106.7 484.6 ± 59.0 
Aromatic 187.5 ± 29.1 154.7 ± 24.8 c 
Essential 995.7 ± 147.2 861.5 ± 125.3a 
EAA/NEAA 0.57 ± 0.06 0.53 ± 0.05 
-----------------------------------------------------------
a- d Concentrations significantly different from that in 
normal controls (Mann Whitney U Test). 
a at P < 0.05 
b at P < 0.02 
c at P < 0.01 
d at P < 0.001 
ND : Not detected in majority of the samples. 
Amino acids included in total amino acid, branched-chain , 
aromatic, essential, and non-essential amino ac i d s were 
defined in Section 3.6. 




Table 4.11 Plasma Amino Acid Concentrations in Lung 
Cancer Patients with No or Minimal Weight Loss (All males). 
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3064.4 ± 427.0 
565.8 ± 145.4 
178.6 ± 35.2 
975.5 ± 207.3 
0.59 ± 0.11 
a-c Concentrations significantly different from that in 
male controls (Mann-Whitney U Test). 
a : at P < 0.05 
b : at P < 0.02 
c : at P < 0.01 
ND : Not detected in majority of the samples. 
Amino acids included in total amino acid, branched-chain, 
aromatic, essential, and non-essential amino acids we r e 
defined in Section 3.6. 
EAA/NEAA : Ratio of essential to non-essential ami no acids. 
65 
Results 
Table 4. 12 : Plasma Amino Acid Concentrations in Breast 
Cancer Patients with No or Minimal Weight Loss (All 
females). (Compared with female normal controls) 
Amino Acid 
Female control 
(n = 10) 
Conc.(J.Lmol/L) 
Mean ± S.D. 
Breast cancer 
(F, n = 11) 
Conc.(J.Lmol/L) 
Mean ± S.D. 
-----------------------------------------------------------
Glutamic acid 33.5 ± 10.5 77.6 ± 21.8d 
Asparagine 51.6 ± 10.6 51.0 ± 13.8 
Serine 132.6 ± 18.4 154.0 ± 33.4a 
Histidine 75.4 ± 20.5 91.3 ± 16.5a 
Glutamine 753.3 ± 93.1 773.7 ± 178.3 
Glycine 255.4 ± 48.8 251.1 ± 57.6 
Threonine 144.9 ± 32.1 174.0 ± 35.1 
Citrulline 26.7 ± 9.8 40.7 ± 15 . 9b 
Arginine 67.S ± 14.9 6S.6 ± 16.0 
3-Methylhistidine 16.2 ± 9.9 20.6 ± 4.6 
Alanine 433.3 ± 89.0 453.6 ± 101.8 
Taurine 50.8 ± 12.1 68.0 ± 20.1 c 
Tyrosine 61.3 ± 11.4 63.3 ± 12.2 
a-Aminobutyric acid 2S.4 ± 8.7 24.9 ± 18.3 
Valine 314.4 ± 61.0 331.8 ± 57.8 
Methionine 10.4 ± 4.2 12.3 ± 2.0 
Tryptophan 54.5 ± 6.7 52.8 ± 12.4 
Phenylalanine 60.2 ± 8.8 69.2 ± 15. la 
Isoleucine 65.1 ± 12.4 78.4 ± 19.7 
Leucine 122.1 ± 22.4 120.7 ± 40.2 
ornithine 55.6 ± 14.9 83.3 ± 20.4c 
Lysine 161.6 ± 24.9 178.1 ± 46.2 
------------------ ------------------------------------
Total amino acid 2960.7 ± 326.1 3300.6 ± 451.6a 
Branched-chain 501.6- ± 86.9 530.8 ± 116.1 
Aromatic 176.0 ± 19.6 185.4 ± 33.4 
Essential 922.7 ± 122.0 1005.0 ± 162.6 
EAA/NEAA 0.55 ± 0.05 0.58 ± 0.Q9 
-----------------------------------------------------------
a-d: Concentrations significantly different from that in 
female controls (Mann Whitney U Test). 
a at P < O.OS 
b at P < 0.02 
c : at P < 0.01 
d : at P < 0.001 
Amino acids included in total amino acid, branched-chain, 
aromatic, essential, and non-essential amino acids we r e 
defined in Section 3.6. 
EAA/NEAA : Ratio of essential to non-essential ami n o acids. 
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Table 4.13 : Plasma Amino Acid Concentrations in Colorectal 


























(n = . 23) 
Conc.(pmol/L) 
Mean ± S.D. 
40.3 ± 18.8 
50.1 ± 10.1 
129.2 ± 16.6 
79.9 ± 17.3 
777.1 ± 119.0 
249.2 ± 43.7 
150.7 ± 29.5 
30.2 ± 10.0 
66.4 ± 13.0 
15.2 ± 8.3 
409.7 ± 89.3 
49.6 ± 10.9 
65.4 ± 12.7 
25.8 ± 8.5 
358.2 ± 81.5 
11.8 ± 4.7 
59.1 ± 10.1 
63.0 ± 11.4 
71.2 ± 15.3 
131.3 ± 25.1 
57.1 ± 15.8 
177.0 ± 32.3 
Colorectal cancer 
(n = 8) 
Conc.(pmol/L) 
Mean ± S.D. 
70.2 ± 43.7 
40.6 ± 8.2b 
125.2 ± 32.1 
68.8 ± 14.4 
777.3 ± 126.1 
205.9 ± 47.7 
103.8 ± 20.2d 
32.4 ± 8.7 
60.6 ± 19.2 
8.2 ± 5.4b 
286.2 ± 91.2c 
56.1 ± 10.7a 
43.5 ± 12.1 d 
25.9 ± 8.1 
294.5 ± 37.3a 
ND 
41.5 ± 12.7c 
54.9 ± 12.4a 
81.6 ± 13.6 
132.8 ± 29.7 
65.9 ± 21.6 
148.3 ± 35. la 
------------------ ------------------------------------
Total amino acid 3574.0 ± 757.5 2757.2 ± 429.4a 
Branched-chain 634.3 ± 84.4 509.0 ± 94.3 
Aromatic 202.5 ± 33.5 141.5 ± 35.4c 
Essential 1114.2 ± 102.2 841.0 ± 152.8b 
EAA/NEAA 0.57 ± 0.02 0.57 ± 0.09 
-----------------------------------------------------------
a-c: Concentrations significantly d ifferent from that in 
normal controls (Mann Whitney U Test). 
a at P < 0.05 
b at P < 0.02 
c at P < 0.01 
d at P < 0.001 
ND : Not detected in majority of the samples. 
Amino acids included in total amino acid, branched-chain, 
aromatic, essential, and non-essent i al amino a cids were 
defined in Section 3.6. 
EAA/NEAA : Ratio of essential to non-esse ntial a mino acids . 
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5.1 METHOD ESTABLISHMENT 
The analytical performance of the HPLC protocol was found 
to be satisfactory (Section 4.1). The protocol is suitable 
for analyzing large number of samples. 
5.2 NORMAL CONTROLS 
The free plasma amino acid concentrations in the normal 
controls in this study agree with the results in a 
published report (Armstrong and Stave, 1973a) in which the 
fasting amino acid profiles in 91 men and 103 women were 
analyzed. The only exception was taurine. The workers of 
that study also admitted that their taurine results were 
higher than those reported in previous studies. They 
thought this was due to the use of platelet-rich plasma. 
Most of the taurine in blood is contained in platelet. 
It was found in this study that there were significant 
differences between men and women in the plasma 
concentrations of ten amino acids (Section 4.4 and Table 
4.9), namely, glutamic acid, histidine, citrulline, 
tyrosine, valine, methionine, tryptophan, isoleuc ine , 
leucine and lysine. Except for glutamic ac i d, they were al l 
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of a lower concentration in the female controls. Among 
them, valine, isoleucine and leucine are branched-chain 
amino acids. These sex-related differences in amino acid 
concentrations were most probably due to the greater 
muscular mass in men. They were also consistent with the 
findings in Armstrong and Stave's work mentioned -above. In 
that study, significant differences in concentration were 
found between men and women for nearly all of the amino 
acids: men had higher concentrations in all amino acids 
except threonine, serine, and glycine. 
Proper recruitment of control subjects is very important in 
amino acid studies. Besides being sex-matched, they have to 
be stable in body weight for the past month. As has been 
mentioned in Section 4.4, when the weight-stable male 
control subjects were compared with weight-stable lung 
cancer patients, there were only four amino acids that were 





different in concentration. 
loss were included for 
eight amino acids we~e 
Since the cancer patients in this study were all newly-;-
diagnosed, most of them had suffered no or minimal weight 
loss (Table 4. 5 to 4. 8 ). The use of normal and heal thy 
subjects for controls should be justified a nd recruitment 
of such heal thy subjects as controls was not difficult . 
6 9 
Discussion 
However, when cancer patients progressed to later stages of 
disease are to be studied, especially the cachectic 
patients, recruitment of controls would be difficult. Most 
of these patients suffer significant weight loss, hence, 
some weight losing 'normal' controls have to be found. Many 
workers used weight-losing non-cancerous chronic disease 
patients as controls for their studies. Examples include 
patients with anorexia nervosa or post-gastrectomy surgery 
(Clarke et al., 1978), hiatus hernia patients (Naini et 
al.,1988), ' and patients with chronic gastric ulceration or 
senile depression (Bennegard et al., 1984). However, the 
plasma amino acid patterns in these patients are affected 
by many metabolic disturbances caused by their chronic 
diseases. Under this condition, cancer-specific amino acid 
disturbances cannot be differentiated from those of chronic 
diseases. 
Besides, age-matching is also important. In a study of the 
variations in plasma free amino acid levels during growth 
and aging, by Armstrong and Stave (1973b), plasma amino 
acid levels were found to increase with age in children and' 
adolescents, and to a greater extent in boys than in girls. 
Plasma levels of two amino acids, cystine and alanine, wer~ 
found to increase throughout life in both sexes. 
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5.3 CANCER PATIENTS 
5.3.1 Nasopharyngeal Cancer 
In the nasopharyngeal cancer patients, the concentrations 
of eight plasma amino acids were significantly lower than 
those in the control subjects (Table 4.10). Among them, 
asparagine, serine and glycine are glucogenic amino acids; 
tyrosine, tryptophan, and phenylalanine are aromatic; and 
valine, phenylalanine and tryptophan are essential amino 
acids. After grouping the amino acids into specific groups 
(Section 3.6), the aromatic amino acid and essential amino 
acid concentrations were significantly lower than those in 
the normal subjects whereas the branched-chain amino acid 
concentrations were similar. Plasma amino acid patterns of 
nasopharyngeal cancer patients were more disturbed than 
expected. Similar studies could not be found for 
comparison, perhaps because of relatively low incidence 
rate of nasopharyngeal carcinoma among the Western 
populations. 
5.3.2 Lung Cancer 
If the results of the two lung cancer patients with 
significant weight loss were excluded, the remaining lung 
cancer patients had only four plasma amino acids with 
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concentration significantly lower than those in the control 
subjects. They were histidine, threonine, a-aminobutyric 
acid and lysine (Table 4.11). Threonine is both essential 
and glucogenic, lysine is essential, and histidine is 
glucogenic. These results agree, in part, with the findings 
of Zhang and Pang's study ( 1992 ). They showed in lung 
cancer patients a decreased level in histidine, threonine, 
a-aminobutyric acid, glutamine, citrulline, arginine, 
alanine, valine, methionine and tryptophan. 
After grouping, no amino acid group in lung cancer patients 
was significantly different from those in the control 
subjects. Therefore, the changes in amino acid profiles in 
lung cancer patients were mild, in fact, the mildest among 
all the cancer types in this study. 
5.3.3 Breast Cancer 
In the breast cancer patients, the concentrations of sev~n 
plasma amino acids (glutamic acid, serine, histidine~ 
citrulline, taurine, phenylalanine and ornithine) were 
significantly different from those in female controls 
(Table 4.12). Except for glutamic acid and serine, their 
concentrations in the breast cancer patients were all 
higher than in the female control group. Among them, 
glutamic acid, serine and histidine are glucogenic amino 
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acids. The total amino acid concentration of the breast 
cancer group was also higher. Levels of branched-chain, 
aromatic and essential amino acids, however, were similar 
between the cancer and control groups. These results were 
similar to those obtained in the study by Kubota et al. 
(1992). They had also demonstrated higher concentrations in 
breast cancer patients for most of the amino acids. 
However, besides glucogenic amino acids, they also showed 
increased essential amino acid, branched-chain amino acid, 
and aromatic amino acid levels in their breast cancer 
patients. The relatively non-specific increase in amino 
acid levels in breast cancer in this study is also 
comparable with the results in the study by Zhang and Pang 
(1992), in which they found that the amino acid profile in 
breast cancer patients was similar to those in normal 
controls. 
The elevated amino acid levels in breast cancer patients 
might be related to their diet. Several studies have shown 
positive correlations between breast cancer mortality and 
consumption of animal proteins (Armstrong and Doll, 1975~ 
Gaskill et al., 1979; Gray et al., 1979). Gray et al., 
(1979) even identified animal proteins as the most highly 
correlated risk factor in breast cancer. 
The breast cancer patients in this study (me d ian age = 42 
years) were, in general, older than the female controls 
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(median age = 35 years). In order to see if the results of 
those older patients had any effects on the group results, 
the breast cancer patients had been divided into two groups 
for comparison; first group aged 24-54, second group aged 
55-93 (54 was the upper age limit of the female control 
group). It was found that there were no significant 
differences between them. Hence, the results of the older 
patients were also included so as not to make the sample 
size too small. 
5.3.4 Colorectal Cancer 
In the colorectal cancer patients, the concentrations of 
ten plasma amino acids were significantly different from 
those in the normal controls (Table 4.13). They were 
asparagine, threonine, 3-methylhistidine, alanine, taurine, 
tyrosine, valine, tryptophan, phenylalanine and lysine. 
Except for taurine, they all had lower concentrations in 
the colorectal cancer patients. Among them, phenylalanine, 
tyrosine and tryptophan are aromatic, and alanine is the 
main gl ucogenic amino acid. After grouping, besides the 
aromatic amino acid concentrations, the essential amino 
acid and total amino acid concentrations were also 
significantly different. The concentrations of branched-
chain amino acids except for valine, however, were still 
maintained normal. Since these patients had malignant 
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tumour in the colorectal region, the absorptive functions 
of their gastrointestinal tracts were probably impaired. 
This might explain why their essential amino acid levels 
were lower than those of the normal controls. The fact that 
these patients were all low or marginally low in plasma 
albumin levels also suggested that they might be suffering 
from mild malnutrition. For plasma branched-chain amino 
acids, since their main site of metabolism is the muscle, 
their levels were not affected. 
5.4 SUMMARY OF THE PLASMA AMINO ACID PROFILES IN CANCER 
Although free amino acids only constitute not more than 1% 
of the total amino acid body pool, they are the 
metabolically active form of nitrogen in human (Pisters and 
Brennan, 1990). This study confirmed the changes of the 
free amino acid patterns in the circulation of cancer 
patients. 
Compared with the control subjects, the total amino acid 
concentration was found to be decreased in colorectal 
cancer but increased in breast cancer. Aromatic amino acid 
\ 
and essential amino acid concentrations were both decreased 
in nasopharyngeal and colorectal cancers. Major glucogenic 
amino acid concentrations were decreased in nasopharyngeal 
and colorectal cancers. Concentrations of branched-chain 
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amino acids were maintained in all the four cancer types. 
These results are summarized in Table 5.1. 
The number of patients was small in each cancer type, 
al though it has already taken nine months for patient 
recruitment. The results of this study cannot be of 
important statistical meaning, but gave a general picture 
of the plasma amino acid profiles in the four types of 
cancer of high incidence in Hong Kong. 
5.5 FURTHER STUDIES 
Patients of the four cancer types recruited for this study 
were small in number. Hence, the study should be continued 
when further patients are diagnosed. More cancer types can 
be included. Longitudinal study on each patient to see the 




Table 5.1 Profiles of Specific Amino Acid Groups in 

















= Nasopharyngeal cancer 
= Total amino acid 
= Branched-chain amino acid 
= Aromatic amino acid 
= Glucogenic amino acid 
= Glycine 
= Alanine 
= Concentration decreased 
= Concentration increased 









There were definite alterations in the plasma free amino 
acid profiles of newly-diagnosed cancer patients. These 
al terations, however, could not be proved to be organ-
specific. Plasma free amino acid profiles in malignancy 
were found not to have diagnostic value in this study. 
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